Bacillus anthracis infections – new possibilities of treatment

Dorota Żakowska 1, Michał Bartoszcze 1, Marcin Niemcewicz 1, Agata Bielawska-Drózd 1, Józef Knap 2, Piotr Cieślik 3, Krzysztof Chomiczewski 4, Janusz Kocik 5
1 - Biological Threats Identification and Countermeasure Centre, Military Institute of Hygiene and Epidemiology, Puławy, Poland
2 - Warsaw Medical University, Department of Epidemiology, Institute of Social Medicine, Warsaw, Poland
3 - Biological Threats Identification and Countermeasure Centre, Military Institute of Hygiene and Epidemiology, Puławy, Poland
4 - Faculty of Chemistry and New Techonlogies, Military University of Technology, Warsaw, Poland
5 - Military Institute of Hygiene and Epidemiology, Warsaw, Poland
Ann Agric Environ Med
2015; 22 (2):
ICID: 1152065
Article type: Review article
Introduction and objective. Bacillus anthracis is one of biological agents which may be used in bioterrorism attacks. The aim of this study a review of the new treatment possibilities of anthrax, with particular emphasis on the treatment of pulmonary anthrax.
Abbreviated description of the state of knowledge. Pulmonary anthrax, as the most dangerous clinical form of the disease, is also extremely difficult to treat. Recently, considerable progress in finding new drugs and suitable therapy for anthrax has been achieved, for example, new antibiotics worth to mentioning, levofloxacin, daptomycin, gatifloxacin and dalbavancin. However, alternative therapeutic options should also be considered, among them the antimicrobial peptides, characterized by lack of inducible mechanisms of pathogen resistance. Very promising research considers bacteriophages lytic enzymes against selected bacteria species, including antibiotic-resistant strains.
Results. Interesting results were obtained using monoclonal antibodies: raxibacumab, cAb29 or cocktails of antibodies. The application of CpG oligodeoxynucleotides to boost the immune response elicited by Anthrax Vaccine Adsorbed and CMG2 protein complexes, also produced satisfying therapy results. Furthermore, the IFN-α and IFN-β, PA-dominant negative mutant, human inter-alpha inhibitor proteins and LF inhibitors in combination with ciprofloxacin, also showed very promising results.
Conclusions. Recently, progress has been achieved in inhalation anthrax treatment. The most promising new possibilities include: new antibiotics, peptides and bacteriophages enzymes, monoclonal antibodies, antigen PA mutants, and inter alpha inhibitors applications. In the case of the possibility of bioterrorist attacks, the examination of inhalation anthrax treatment should be intensively continued.

DOI: 10.5604/12321966.1152065
PMID 26094508 - click here to show this article in PubMed

Recommend this article to:


Related articles in IndexCopernicus™
     treatment [1756 related records]
     Peptides [199 related records]
     inhalational anthrax [0 related records]
     Antibodies [285 related records]
     antibiotics [261 related records]


Related articles

K Babu, B Joshi,
Medical Management of Surgical Appendix...
Objective: The aim of this study is to evaluate the feasibility and safety of non operative [1,2] treatment of acute appendicitis with antibiotics [1,2,3] and avoiding surgery. Although the standard treatment of acute appendicitis [since 1883] is...
A García,
El estudio del delincuente requiere de una intervención multidisciplinaria ya que es un fenómeno multifactorial; resultando lógico que el tratamiento del delincuente obedezca a una diversidad de análisis por parte de la Ingeniería ortoconductual...
Clinical observation of 18 cases of adult rare liv...
Objective To investigate the diagnosis and treatment of adult rare liver tumors or tumor-like lesins. Methods The clinical data of 18 cases of rare liver tumors or tumor-like lesions were collected from June 2009 to May 2015. The clinical diagnosis a...